On June 10, 2021 AUM LifeTech, Inc., a preclinical stage biotechnology company, reported that it has been selected by the National Institutes of Health (NIH) to present an update on their drug development pipeline at 2021 BIO Digital, the premier biotech event (Press release, AUM Lifetech, JUN 10, 2021, View Source [SID1234583853]). The company has leveraged a self-delivering non-viral RNA targeting technology for therapeutic development in oncology, CNS, and infectious diseases.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Veenu Aishwarya, Founder and Chief Executive Officer of AUM LifeTech, will present an update on their therapeutic programs. "We are honored to be selected by the NIH to showcase our preclinical developments at BIO 2021. We are very excited about our recent encouraging preclinical data as we move towards the next stages of development," said Aishwarya. "Our therapeutic programs, designed for patients with unmet clinical needs, are now ready for collaborations and strategic alliances to further advance our significantly de-risked preclinical assets," he added.
We are very excited about our recent encouraging preclinical data as we move towards the next stages of development.
AUM LifeTech has developed their preclinical pipeline in cancer immunotherapy with a focus on lung cancer using their proprietary RNA targeting technology. Additionally, their programs in CNS and infectious diseases include therapeutic development for Parkinson’s disease and HIV respectively. AUM LifeTech’s HIV preclinical program is funded by the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH. Their drug development pipeline is based on self-delivering FANA antisense oligonucleotide (FANA ASO) technology.
BIO Digital is scheduled June 10-11 & 14-18, 2021, and AUM LifeTech’s therapeutic developments and insight into their gene silencing technology and preclinical research will be available to registered attendees at 9 am ET on June 10. Attendees at BIO Digital will be able to view the presentation by AUM LifeTech as part of the NIH Innovation Zone before live meetings in the BIO One-on-One Partnering system begin on June 14. To meet with AUM LifeTech at BIO Digital, you can find registration information here.